Methylthiouracil
Based on 1 publication(s) in Google Scholar
Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 56-04-2
- Formule: C5H6N2OS
- Masse moléculaire:142.18
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Nucleotide Compound Library
HY-L044
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Pyroptosis Compound Library
HY-L059
-
Glutamine Metabolism Compound Library
HY-L064
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Tumorigenesis-Related Compound Library
HY-L100
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
-
FDA Kinase Inhibitor Library
HY-L230
-
Lactylation Compound Library
HY-L249
-
Drug Fragment Library
HY-L904
Publications Citing Use of MedChemExpress (MCE) Methylthiouracil
More
Customer Validation & Images
-
Cell Migration/Invasion Assay
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
|
NF-κB |
IL-6 |
ERK1 |
ERK2 |
HUVECs are treated with various concentrations of MTU (0-20 μM) for 6 h after the addition of LPS (100 ng/mL) for 4 h. MTU inhibits LPS-mediated hyperpermeability in endothelial cells, with the optimal effect occurring at a concentration above 5 μM. The effects of MTU are examined on HUVEC actin cytoskeletal arrangement by immunofluorescence staining of HUVEC monolayers with F-actin labeled fluorescein phalloidin. Control HUVECs exhibit a random distribution of F-actin throughout the cells, with some localization of actin filament bundles at the cell boundaries. Barrier disruption by LPS (100 ng/mL) is manifested by the formation of paracellular gaps in HUVECs. In addition, post-treatment with MTU (10 or 20 μM) results in inhibited formation of LPS-induced paracellular gaps with the formation of dense F-actin rings. To test the cytotoxicity of MTU, cellular viability assays are performed in HUVECs treated with MTU for 24 h. At concentrations up to 20 μM, MTU does not affect cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Methylthiouracil can be used to model neurological defects. Methylthiouracil can significantly inhibit LPS-induced peritoneal dye leakage. In the mouse model, the average circulating blood volume was 72 mL/kg (average mouse weight 27 g) and the average blood volume was about 2 mL. After injection of Methylthiouracil (142 or 284 μg/kg), the dye concentration in peripheral blood reached a maximum of 10 or 20 μM, respectively. In dairy cows, after oral administration, Methylthiouracil rapidly appears in plasma, urine, and milk, and accumulates selectively in the thyroid gland. Its excretion follows a biphasic pattern. At the beginning of treatment, the level of Methylthiouracil drops rapidly within 4 days, and then the excretion rate slows down by 15-30 times. Long-term use of Methylthiouracil results in significant residues that can still be detected in the thyroid gland, muscle tissue, urine, and plasma one month after stopping administration[1][2][3].
Administration: 0.05-0.2 mL • sc • once daily, details of the dosing method are provided in the note
(1). From 0-10 days after birth, 0.05 mL of the suspension is administered via subcutaneous injection;
(2). From 10-20 days after birth, 0.1 mL of the suspension is administered via subcutaneous injection;
(3). From 20-24 days after birth, 0.2 mL of the suspension is administered via subcutaneous injection.
Histological Changes: In the cerebral cortex of the rats, the volume of pyramidal cells decreased, their number increased, and the supportive or structural substance (intercellular matrix) between neurons in the cerebral cortex decreased during the rats' development.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 56-04-2
-
Appearance Solid
-
Masse moléculaire 142.18
-
Formule C5H6N2OS
-
Color White to off-white
-
SMILES
O=C(C=C(C)N1)NC1=S
-
Synonyms
MTU
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Hepatol Commun
Proteomics-based identification of the role of osteosarcoma amplified-9 in hepatocellular carcinoma recurrence. [Abstract]2022 Aug;6(8):2182-2197. PMID: 35429130
Methylthiouracil purchased from MedChemExpress. Usage Cited in: Hepatol Commun. 2022 Aug;6(8):2182-2197. [Abstract]
Effect of OS-9 overexpression group treated with TNFα inhibitor (Methylthiouracil, 20 μM) on SMMC-7721 cell migration capacity is assessed.
Solvant et solubilité
DMSO : ≥ 50 mg/mL (351.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (17.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
MTT is used as an indicator of cell viability. Primary human umbilical vein endothelial cells (HUVECs) are grown in 96-well plates at a density of 5×103 cells/well. After 24 h, the cells are washed with fresh medium and treated with MTU (0-20 μM). After a 48 h incubation period, the cells are washed, and 100 μL of MTT (1 mg/mL) is added, followed by incubation for 4 h. Finally, DMSO (150 μL) is added to solubilize the formazan salt formed, and the amount of formazan salt is determined by measuring the OD at 540 nm using a microplate reader [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
Male C57BL/6 mice (6-7 weeks old; average weight, 27 g) are used in this study. Mice are administered LPS (0.3 mg/mouse or 15 mg/kg, intravenously). After 4 h, the mice are intravenously treated with MTU (142 or 284 μg/kg, for 6 h) and injected with 1% Evans blue dye solution in normal saline. Six hours later, the mice are sacrificed and peritoneal exudates are collected by washing cavities with 5 mL of normal saline and by centrifuging at 200× g for 10 min. The absorbance of the supernatant is read at 650 nm. Vascular permeabilities are expressed as μg of dye/mouse that leaked into the peritoneal cavity and are determined using a standard curve.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (310 KB)
-
SDS (617 KB)
- English - EN (617 KB)
- Français - FR (617 KB)
- Deutsch - DE (617 KB)
- Norwegian - NO (617 KB)
- Español - ES (617 KB)
- Swedish - SV (617 KB)
- Italian - IT (617 KB)
- Korean - KR (617 KB)
- Portuguese - PT (617 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ku SK, et al. Anti-inflammatory effects of methylthiouracil in vitro and in vivo. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):374-86. [Content Brief]
[2]. Heeremans A, et al. Elimination profile of methylthiouracil in cows after oral administration. Analyst. 1998 Dec;123(12):2629-32. [Content Brief]
[3]. EAYRS JT, et al. The effect of thyroid deficiency induced by methyl thiouracil on the maturation of the central nervous system. J Anat. 1951 Oct;85(4):350-8. [Content Brief]
[4]. Coda AR, et al. In vivo imaging of CNS microglial activation/macrophage infiltration with combined [18F]DPA-714-PET and SPIO-MRI in a mouse model of relapsing remitting experimental autoimmune encephalomyelitis. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):40-52. [Content Brief]
[5]. Hofstetter HH, et al. Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol. 2007 Feb 1;178(3):1372-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 7.0333 mL | 35.1667 mL | 70.3334 mL | 175.8335 mL |
| 5 mM | 1.4067 mL | 7.0333 mL | 14.0667 mL | 35.1667 mL | |
| 10 mM | 0.7033 mL | 3.5167 mL | 7.0333 mL | 17.5833 mL | |
| 15 mM | 0.4689 mL | 2.3444 mL | 4.6889 mL | 11.7222 mL | |
| 20 mM | 0.3517 mL | 1.7583 mL | 3.5167 mL | 8.7917 mL | |
| 25 mM | 0.2813 mL | 1.4067 mL | 2.8133 mL | 7.0333 mL | |
| 30 mM | 0.2344 mL | 1.1722 mL | 2.3444 mL | 5.8611 mL | |
| 40 mM | 0.1758 mL | 0.8792 mL | 1.7583 mL | 4.3958 mL | |
| 50 mM | 0.1407 mL | 0.7033 mL | 1.4067 mL | 3.5167 mL | |
| 60 mM | 0.1172 mL | 0.5861 mL | 1.1722 mL | 2.9306 mL | |
| 80 mM | 0.0879 mL | 0.4396 mL | 0.8792 mL | 2.1979 mL | |
| 100 mM | 0.0703 mL | 0.3517 mL | 0.7033 mL | 1.7583 mL |
Methylthiouracil Related Classifications
HY-B0513 Related Classifications
Powered by Bioz